Here are relevant reports on : gastrointestinal-cancer-therapeutics-market
-
Endoluminal Suturing Devices Market Size, Growth by Application (Bariatric, Gastrointestinal, Gastroesophageal Reflux Disease), End User (Hospitals, Clinics, Ambulatory Surgical Centers), Technology Analysis, Regulatory Landscape, Trends - Global Forecasts to 2027
The global endoluminal suturing devices market in terms of revenue was estimated to be worth $78 million in 2022 and is poised to reach $139 million by 2027, growing at a CAGR of 12.0% from 2022 to 2027. The prominent players in this market are Apollo Endosurgery, Inc. (US), Johnson & Johnson (US), Medtronic Plc (Ireland), Cook Group Incorporated (US), USGI Medical (US), Ovesco Endoscopy AG (Germany), Endo Tools Therapeutics S.A. (Belgium), ErgoSuture (US), and Sutrue Ltd. (UK).
- Published: August 2022
- Price: $ 4950
- TOC Available:
-
Human Microbiome Manufacturing Services Market by Type (Fermentation & Downstream Processing, Strain Development & Optimization), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease) - Global Forecast to 2031
Human Microbiome Manufacturing Services Market by Type (Fermentation & Downstream Processing, Strain Development & Optimization), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease) - Global Forecast to 2031
- Published: December 2025
- Price: $ 4950
- TOC Available:
-
North America Human Microbiome Market By Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The North America human microbiome market is expected to grow from USD 0.78 billion in 2025 to USD 4.15 billion in 2031, at a compound annual growth rate (CAGR) of 32.2% during the forecast period. The Key Players Seres Therapeutics (US), Seed Health, Inc. (US), International Flavors & Fragrances Inc. (US), Pendulum (US), Biohm Technologies (US), Resbiotic (US), Infinant Health Inc. (US), and ExeGi Pharma (US).
- Published: December 2025
- Price: $ 4950
- TOC Available:
-
Minimally Invasive Surgical Instruments Market by Product (Handheld, Inflation Devices, Surgical Scopes), Type of Surgery (Cardiothoracic, Gastrointestinal, Bariatric, Orthopedic, Urological), Technology (Non-robotic, Robotic) - Global Forecast to 2029
The global minimally invasive surgical instruments market, valued at US$29.9 billion in 2023, stood at US$31.7 billion in 2024 and is projected to advance at a resilient CAGR of 9.5% from 2024 to 2029, culminating in a forecasted valuation of US$49.9 billion by the end of the period. The growth of this market is primarily fueled by the rising prevalence of surgical procedures globally, the advantages of minimally invasive surgery over traditional open techniques, and the increasing use of advanced robotics in ambulatory surgical centers.
- Published: June 2024
- Price: $ 4950
- TOC Available:
-
Primary Cells Market by Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Pharma Biotech, CROs, Academia), Region - Global Forecast to 2028
The global primary cells market, valued at US$1.5 billion in 2022, stood at US$1.7 billion in 2023 and is projected to advance at a resilient CAGR of 10.5% from 2023 to 2028, culminating in a forecasted valuation of US$2.8 billion by the end of the period. The growth of this market can be attributed to factors such as the is the growing advantages of primary human cells over cell lines, rising growth in pharmaceutical & biotechnology industries, increasing demand for monoclonal antibodies, Government investments for cell-based research, and increasing cancer research.
- Published: July 2023
- Price: $ 4950
- TOC Available:
-
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031
The global human microbiome market, valued at US$0.91 billion in 2024, stood at US$1.40 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$7.09 billion by the end of the period. North American market held the largest share during the forecast period due to the rising investments by governments and industries, and presence of a strong human microbiome ecosystem supporting innovation in this field.
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
Surgical Procedures Market by Type (Gastrointestinal, Cardiovascular, Dental, Cosmetic, Urologic, Ophthalmic, Orthopedic, ENT, Nervous System, Obstetric/Gynecologic), Channel (Physician Offices, Hospitals, ASCs) - US Forecast to 2028
The global surgical procedures market, valued at US$1,02,005.3 thousand procedures in 2021, stood at US$1,08,275.5 thousand procedures in 2023 and is projected to advance at a resilient CAGR of 3.4% from 2023 to 2028, culminating in a forecasted valuation of US$1,27,748.5 thousand procedures by the end of the period. The growth of the US market is largely driven by the growing prevalence of chronic diseases, the rising geriatric population, advancements in surgical techniques, and increased investment in health facilities.
- Published: June 2023
- Price: $ 4950
- TOC Available:
-
Surgical Anastomosis Devices Market by Product, (Surgical Sutures, Surgical Staplers), Application (Cardiovascular, Gastrointestinal) - Global Forecast to 2023
Anastomosis is a connection made surgically between adjacent blood vessels, parts of the intestine, or other channels of the body. It is achieved by surgically suturing or stapling the two ends of the channel to restore or form a new connection. Vascular anastomosis is performed to connect the blood vessels, for e.g. in cardio vascular surgeries such as by-pass surgery. Similarly, gastrointestinal anastomosis is performed for bowel re-sectioning, for e.g. in Gastrojejunostomy. With increasing ailments of cardiovascular diseases, gastrointestinal surgeries, and organ transplants has resulted in demand for anastomosis devices.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Europe Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics, Synbiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Europe human microbiome market is expected to reach USD 1.31 billion by 2031, up from USD 0.29 billion in 2025, with a CAGR of 28.6% over the forecast period. Some of the leading players in the market include Ferring B.V. (Switzerland), OptiBiotix Health PLC (UK), BioGaia (Sweden), MaaT Pharma (France), Actial Farmaceutica srl (Italy), and nfant Bacterial Therapeutics AB. (Sweden), OxThera (Sweden), and Nexbiome (France), among others.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Immunotherapy Drugs Market by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Global Forecast to 2029
The global immunotherapy drugs market, valued at US$255.9 billion in 2023, stood at US$285.3 billion in 2024 and is projected to advance at a resilient CAGR of 15.3% from 2024 to 2029, culminating in a forecasted valuation of US$580.6 billion by the end of the period. This growth is driven by technological advancements in antibody engineering, increasing demand for antibody therapies in clinical cancer treatment, and a growing preference for personalized medicines and targeted therapies.
- Published: July 2024
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
